Patents by Inventor Markus Maegerlein
Markus Maegerlein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10653625Abstract: A method is described for the production of dosage forms, which comprise a solid dispersion of a microcrystalline active substance, in which a thermoplastic polymer with a glass transition temperature Tg of at least 40° C. is melted and an active substance is dissolved homogeneously in the melt; crystallization of the active substance is initiated in the mass obtained; and the mass is cooled. Crystallization of the active substance can be initiated by adding a nonsolvent, seed crystals of the active substance or a derivatization reagent. In addition, crystallization can be initiated by holding the mass for a sufficient length of time at a temperature that is below the temperature at which the active substance is completely soluble in the mass.Type: GrantFiled: February 9, 2006Date of Patent: May 19, 2020Assignee: Abbvie Deutschland GmbH & Co. KGInventors: Jörg Rosenberg, Markus Mägerlein, Bernd Liepold, Jörg Breitenbach
-
Patent number: 9402909Abstract: A pharmaceutical dosage form comprises a solid dispersion product of at least one active ingredient dispersed in a polymeric binder composition, the polymeric carrier composition comprising a) a vinylpyrrolidone homopolymer, wherein at least 95% by weight of the vinylpyrrolidone homopolymer has a molecular weight distribution within the range of from 1000 to 13 000; and b) a vinylpyrrolidone copolymer having a weight-average molecular weight of from 5000 to 1 500 000. The dosage form is preferably prepared by a melt extrusion process. The polymeric carrier composition exhibits a high drug dissolution power and allows a reduction of the viscosity of the melt without deteriorating the mechanical properties and storage stability of the dosage form.Type: GrantFiled: January 10, 2014Date of Patent: August 2, 2016Assignee: Abbvie Deutschland GmbH & Co KGInventors: Bernd Liepold, Jörg Breitenbach, Markus Mägerlein, Claudia Henzel, Thomas K. Kessler
-
Patent number: 9174944Abstract: This invention relates to novel crystalline lopinavir/surfactant adducts, methods for their preparation, therapeutic uses of those crystalline lopinavir/surfactant adducts, and pharmaceutical compositions containing them or made from them.Type: GrantFiled: December 16, 2011Date of Patent: November 3, 2015Assignee: ABBVIE INC.Inventors: Yuchuan Gong, Geoff G. Zhang, Matthias Degenhardt, Markus Maegerlein
-
Patent number: 9149431Abstract: A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35>?Htr (1) (wherein ?Htr represents the endotherm (J/g) accompanying a transition at about 240° C.). The solid dispersion product shows an improved bioavailability.Type: GrantFiled: June 21, 2013Date of Patent: October 6, 2015Assignees: Abbvie Deutschland GmbH & Co KG, Barrier Therapeutics, Inc.Inventors: Gunther Berndl, Matthias Degenhardt, Markus Mägerlein, Gerrit Dispersyn
-
Patent number: 9060936Abstract: A solid dispersion product comprising an effective amount of one or more active ingredients and an effective amount of one or more hydroxypropyl methylcellulose(s), which satisfies the Formula 0.35>?Htr (1) (wherein AHtr represents the endotherm (J/g) accompanying a transition at about 240° C.). The solid dispersion product is used for the manufacture of a dosage form having improved bioavailability of said one or more active ingredients by oral administration to a patient in need thereof.Type: GrantFiled: June 21, 2011Date of Patent: June 23, 2015Assignee: Abbvie Deutschland GmbH & Co. KGInventors: Gunther Berndl, Matthias Degenhardt, Markus Maegerlein
-
Patent number: 9004752Abstract: A viable strategy to enhance the bioavailability of poorly soluble drugs is to use amorphous solids in place of the more commonly used crystalline solids in pharmaceutical formulations. However, amorphous solids are physically meta-stable and tend to revert back to their crystalline counterpart. An effective approach to stabilizing an amorphous drug against crystallization is to disperse it in a polymer matrix. The drug's solubility in the chosen polymer defines the upper limit of drug loading without any risk of crystallization. Measuring the solubility of a drug in a polymer has been a scientific and technological challenge because the high viscosity of polymers makes achieving solubility equilibrium difficult and because pharmaceutically important drug/polymer dispersions are glasses, which undergo structural relaxation over time. The invention provides a method based on Differential Scanning calorimetry (DSC) for measuring the solubility of crystalline drugs in polymeric matrices.Type: GrantFiled: April 29, 2009Date of Patent: April 14, 2015Assignees: Abbvie, Inc., Abbvie Deutschland GmbH & Co KG, Wisconsin Alumni Research FoundationInventors: Geoff G. Zhang, Lian Yu, Jing Tao, Ye Sun, Markus Maegerlein
-
Publication number: 20140200278Abstract: A pharmaceutical dosage form comprises a solid dispersion product of at least one active ingredient dispersed in a polymeric binder composition, the polymeric carrier composition comprising a) a vinylpyrrolidone homopolymer, wherein at least 95% by weight of the vinylpyrrolidone homopolymer has a molecular weight distribution within the range of from 1000 to 13 000; and b) a vinylpyrrolidone copolymer having a weight-average molecular weight of from 5000 to 1 500 000. The dosage form is preferably prepared by a melt extrusion process. The polymeric carrier composition exhibits a high drug dissolution power and allows a reduction of the viscosity of the melt without deteriorating the mechanical properties and storage stability of the dosage form.Type: ApplicationFiled: January 10, 2014Publication date: July 17, 2014Applicant: Abbvie Deutschland GmbH & Co. KGInventors: Bernd Liepold, Jörg Breitenbach, Markus Mägerlein, Claudia Henzel, Thomas K. Kessler
-
Publication number: 20140005204Abstract: A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35>?Htr (1) (wherein ?Ht, represents the endotherm (J/g) accompanying a transition at about 240° C.). The solid dispersion product shows an improved bioavailability.Type: ApplicationFiled: June 21, 2013Publication date: January 2, 2014Inventors: Gunther Berndl, Matthias Degenhardt, Markus Mägerlein, Gerrit Dispersyn
-
Publication number: 20130199313Abstract: A method for evaluating the solubility of a crystalline substance in a polymer comprises a) providing at least one sample of an intimate crystalline substance/polymer mixture at a predetermined crystalline substance concentration; b) annealing the sample at a constant temperature Ta for a period of time; c) heating the annealed sample while recording the heat flux over time by DSC; d) identifying a DSC dissolution endotherm in the recorded heat flux, if any; e) considering the crystalline substance concentration as a concentration above the crystalline substance solubility in the polymer at temperature Ta when there is a DSC dissolution endotherm identified, and considering the crystalline substance concentration as a concentration less than or equal to the crystalline substance solubility in the polymer at temperature Ta when there is no DSC dissolution endotherm identified.Type: ApplicationFiled: March 14, 2013Publication date: August 8, 2013Applicants: Abbott GmbH & Co, KGW, Boards of Regents of the University of Wisconsin System, AbbVie Inc.Inventors: Geoff G. Zhang, Lian Yu, Jing Tao, Markus Maegerlein
-
Patent number: 8486456Abstract: A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35>?Htr (1) (wherein ?Htr represents the endotherm (J/g) accompanying a transition at about 240° C). The solid dispersion product shows an improved bioavailability.Type: GrantFiled: August 8, 2006Date of Patent: July 16, 2013Assignee: Abbott GmbH & Co., KGInventors: Gunther Berndl, Matthias Degenhardt, Markus Mäegerlein, Gerrit Dispersyn
-
Publication number: 20110311595Abstract: A solid dispersion product comprising an effective amount of one or more active ingredients and an effective amount of one or more hydroxypropyl methylcellulose(s), which satisfies the Formula 0.35>?Htr (1) (wherein AHtr represents the endotherm (J/g) accompanying a transition at about 240° C.). The solid dispersion product is used for the manufacture of a dosage form having improved bioavailability of said one or more active ingredients by oral administration to a patient in need thereof.Type: ApplicationFiled: June 21, 2011Publication date: December 22, 2011Applicant: Abbott GmbH & Co. KGInventors: Gunther Berndl, Matthias Degenhardt, Markus Maegerlein
-
Publication number: 20110261857Abstract: A viable strategy to enhance the bioavailability of poorly soluble drugs is to use amorphous solids in place of the more commonly used crystalline solids in pharmaceutical formulations. However, amorphous solids are physically meta-stable and tend to revert back to their crystalline counterpart. An effective approach to stabilizing an amorphous drug against crystallization is to disperse it in a polymer matrix. The drug's solubility in the chosen polymer defines the upper limit of drug loading without any risk of crystallization. Measuring the solubility of a drug in a polymer has been a scientific and technological challenge because the high viscosity of polymers makes achieving solubility equilibrium difficult and because pharmaceutically important drug/polymer dispersions are glasses, which undergo structural relaxation over time. The invention provides a method based on Differential Scanning calorimetry (DSC) for measuring the solubility of crystalline drugs in polymeric matrices.Type: ApplicationFiled: April 29, 2009Publication date: October 27, 2011Applicant: Abbott GmbH & Co. KGInventors: Geoff G. Zhang, Lian Yu, Jing Tao, Ye Sun, Markus Maegerlein
-
Publication number: 20110182891Abstract: A pharmaceutical dosage form comprises a solid dispersion product of at least one active ingredient dispersed in a polymeric binder composition, the polymeric carrier composition comprising a) a vinylpyrrolidone homopolymer, wherein at least 95% by weight of the vinylpyrrolidone homopolymer has a molecular weight distribution within the range of from 1000 to 13 000; and b) a vinylpyrrolidone copolymer having a weight-average molecular weight of from 5000 to 1 500 000. The dosage form is preferably prepared by a melt extrusion process. The polymeric carrier composition exhibits a high drug dissolution power and allows a reduction of the viscosity of the melt without deteriorating the mechanical properties and storage stability of the dosage form.Type: ApplicationFiled: June 30, 2009Publication date: July 28, 2011Applicant: Abbott GmbH & Co., KGInventors: Bernd Liepold, Jörg Breitenbach, Markus Mägerlein, Claudia Packhäuser, Thomas K. Kessler
-
Publication number: 20100297223Abstract: A pharmaceutical dosage form, comprising a) a liquid or flowable core, b) a shell of a polysaccharide or proteinaceous material completely enclosing said core, the core comprising an active ingredient dissolved in a pharmaceutically acceptable compound of the formula (I) wherein n is an integer from 3 to 5, and wherein the (i) the at least one active ingredient and the compound of the formula (I) account for at least 50% by weight of the composition; and (ii) the water activity aw of the composition is less than 0.4.Type: ApplicationFiled: December 18, 2008Publication date: November 25, 2010Applicant: ABBOTT GMBH & CO. KGInventors: Jörg Rosenberg, Markus Mägerlein, Jörg Breitenbach, Tina Jung, Ulrich Westedt
-
Publication number: 20090220596Abstract: A composition which comprises a solid or semi-solid matrix having at least one active ingredient uniformly dispersed therein, the matrix comprising at least one pharmaceutically acceptable matrix-forming agent and a 1,3-bis(lactamyl)-butane compound, in particular 1,3-bis(pyrrolidon-1-yl)-butane. The active ingredient is preferably dispersed in the matrix in a state of a solid solution. The matrix-forming agent is preferably a pharmaceutically acceptable polymer. The composition is useful for the manufacture of pharmaceutical dosage forms.Type: ApplicationFiled: June 22, 2006Publication date: September 3, 2009Applicant: Abbott GmbH & Co. KGInventors: Jörg Rosenberg, Markus Mäegerlein, Jörg Breitenbach
-
Publication number: 20090214656Abstract: A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35>?Htr (1) (wherein ?Htr represents the endotherm (J/g) accompanying a transition at about 240° C). The solid dispersion product shows an improved bioavailability.Type: ApplicationFiled: August 8, 2006Publication date: August 27, 2009Applicants: ABBOTT GMBH & CO. KG, BARRIER THERAPEUTICSInventors: Gunther Berndl, Matthias Degenhardt, Markus Mäegerlein, Gerrit Dispersyn
-
Publication number: 20090028938Abstract: A solid dispersion product comprising an effective amount of one or more active ingredients and an effective amount of one or more hydroxypropyl methylcellulose(s), which satisfies the Formula 0.35>?Htr (1) (wherein ?Htr represents the endotherm (J/g) accompanying a transition at about 240° C.). The solid dispersion product is used for the manufacture of a dosage form having improved bioavailability of said one or more active ingredients by oral administration to a patient in need thereof.Type: ApplicationFiled: August 8, 2006Publication date: January 29, 2009Applicant: Abbott GmbH & Co. KGInventors: Gunther Berndl, Matthias Degenhardt, Markus Maegerlein
-
Publication number: 20070190142Abstract: A dosage form and method for the delivery of drugs, particularly drugs of abuse, characterized by resistance to solvent extraction, tampering, crushing, or grinding, and providing an initial burst of release of drug followed by a prolonged period of controllable drug release.Type: ApplicationFiled: January 22, 2007Publication date: August 16, 2007Applicant: Abbott GmbH & Co. KGInventors: Jorg BREITENBACH, Ute Lander, Jorg Rosenberg, Markus Maegerlein, Gerd Woehrle
-
Publication number: 20030153608Abstract: Stable pharmaceutical preparations, comprising torasemide in noncrystalline form.Type: ApplicationFiled: December 6, 2002Publication date: August 14, 2003Inventors: Markus Maegerlein, Thomas Hantke, Jorg Breitenbach, Jorg Rosenberg
-
Publication number: 20030119882Abstract: The present invention relates to a solid pharmaceutical composition, comprisingType: ApplicationFiled: October 17, 2002Publication date: June 26, 2003Inventor: Markus Maegerlein